Johnson & Johnson (JNJ)
Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor
ICONIC-LEAD achieved its co-primary endpoints of PASI-90 and IGA of 0 or 1 at week 16; 74% of patients achieved clear or almost clear skin (IGA 0/1) at week 24 ICONIC-TOTAL achieved its primary endpoint of IGA score of 0 or 1 at week 16 in patients with plaque psoriasis in difficult-to-treat areas Protagonist has earned a $165 million milestone under the terms of recently amended agreement, inclusive of $50 million in accelerated payments NEWARK, CA / ACCESSWIRE / November 18, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced positive topline results from its collaboration with Johnson & Johnson, in ICONIC-LEAD 1 and ICONIC-TOTAL 2, two pivotal Phase 3 investigational studies of icotrokinra (JNJ-2113, formerly PN-235), the first-in-class targeted oral peptide that selectively blocks the IL-23 receptor, in individuals 12 years of age and older with moderate to severe plaque psoriasis (PsO). In the ICONIC-LEAD study, once-daily icotrokinra showed significant skin clearance versus placebo in adults and adolescents with moderate to severe plaque psoriasis.
Johnson & Johnson (JNJ) Management presents at Stifel 2024 Healthcare Conference (Transcript)
Johnson & Johnson (NYSE:JNJ ) Stifel 2024 Healthcare Conference November 18, 2024 10:55 AM ET Company Participants Michael Bodner - Group President, Heart Recovery and Circulatory Restoration Conference Call Participants Rick Wise - Stifel Rick Wise Okay everybody, Rick Wise again here and it is my pleasure and truly my privilege to welcome J&J to the 2024 Stifel Healthcare Conference. To my left, Michael Bodner, Group President, Heart Recovery and Circulatory Restoration.
CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC
The CHMP's opinion is based on late-stage study data, which show that treatment with JNJ's combo drug reduces the risk of disease progression or death by 30% in certain NSCLC patients.
Johnson & Johnson (JNJ) Guggenheim Global Healthcare Conference (Transcript)
Johnson & Johnson (NYSE:JNJ ) Guggenheim Global Healthcare Conference November 12, 2024 10:30 AM ET Company Participants Biljana Naumovic - Worldwide VP, Global Commercial Strategy, Oncology Mark Wildgust - VP, Global Medical Affairs Oncology Conference Call Participants Vamil Divan - Guggenheim Securities Edouard Mullarky - Guggenheim Securities Vamil Divan All right. I think we're ready to get started.
2 Of The Cheapest, High-Quality Dividend Stocks On The Market
In today's market, sticky inflation and elevated valuations make stock picking a challenge. But some dividend stocks still stand out as strong, long-term picks. These two dividend stocks offer growth potential and inflation protection. They're built to thrive in today's economic climate, offering stability and income. Even with market volatility, these picks have the ability to deliver consistent returns. Their solid fundamentals and strong business models provide confidence.
Why Is Johnson & Johnson (JNJ) Down 6.7% Since Last Earnings Report?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
Johnson & Johnson: Tracking Well Above The Industry
In the second half of 2024, Johnson & Johnson made significant progress in developing its oncology franchise. So, Darzalex sales were $3.02 billion in the third quarter of 2024, up 20.7% year-on-year, thanks in part to its label expansions. Moreover, on November 8, 2024, the company announced the filing of regulatory applications to the FDA and EMA seeking approval of Darzalex Faspro for the treatment of high-risk smoldering MM.
Johnson & Johnson Enters Oversold Territory
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
US FDA approves Johnson & Johnson's device for heart condition
The U.S. Food & Drug Administration has approved Johnson & Johnson's device for a type of heart condition, the company said on Thursday.
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Johnson & Johnson: Q3 Earnings Highlights Resilience And New Growth
J&J's Q3 2024 earnings beat expectations with $22.5B in revenue, driven by strong performances from Darzalex, STELARA, and MedTech, despite ongoing challenges. The company updated its full-year guidance, showing optimism despite headwinds like talc litigation and STELARA generic competition, maintaining strong cash flow and dividend payouts. New growth opportunities in oncology and MedTech segments, along with strategic acquisitions, are expected to offset potential declines in STELARA sales due to generics.
